Tempest Therapeutics Inc

NASDAQ TPST

Data sourced from

and

Daily

Download Data

Tempest Therapeutics Inc Price to Book Ratio (P/B) on June 03, 2024: 3.50

Tempest Therapeutics Inc Price to Book Ratio (P/B) is 3.50 on June 03, 2024, a 90.97% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Tempest Therapeutics Inc 52-week high Price to Book Ratio (P/B) is 1,716.35 on August 10, 2023, which is 48,942.51% above the current Price to Book Ratio (P/B).
Tempest Therapeutics Inc 52-week low Price to Book Ratio (P/B) is -115.78 on October 11, 2023, which is -3,408.27% below the current Price to Book Ratio (P/B).
Tempest Therapeutics Inc average Price to Book Ratio (P/B) for the last 52 weeks is -6.75.

NASDAQ: TPST

Tempest Therapeutics Inc

CEO	Mr. Stephen R. Brady J.D., LLM
IPO Date	Nov. 12, 2012
Location	United States
Headquarters	7000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	17
Sector	Healthcare
Industry	Biotechnology

Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Key trends